Some clinical laboratories, such as Ambry Genetics, Invitae, and GeneDx, offer prostate cancer-specific panels that include the following genes: ATM, BRCA1, BRCA2, CHEK2, HOXB13, MLH1, MSH2, MSH6, NBN, PALB2, PMS2, and TP53. Evidence is emerging that genetic information can guide treatment modalities, hence the need to better understand genetic risk factors associated with the risk of aggressive prostate cancer. Here, CHEK2 is linked to prostate cancer.